drugset / Trial / NCT00054470
Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast Cancer
Phase 2
Withdrawn
The University of Texas Health Science Center at San Antonio
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining tipifarnib with trastuzumab may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining tipifarnib with trastuzumab in treating patients who have metastatic breast cancer.
Timeline
- Start
- 2002-12
- Primary completion
- 2003-01
- Completion
- 2003-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trastuzumab | Monoclonal antibody | — | Intravenous |
| Subject | tipifarnib | Small molecule | — | Oral |